2.27
+0.01(+0.44%)
Currency In USD
| Previous Close | 2.26 |
| Open | 2.26 |
| Day High | 2.29 |
| Day Low | 2.22 |
| 52-Week High | 10.54 |
| 52-Week Low | 1.11 |
| Volume | 227,466 |
| Average Volume | 247,185 |
| Market Cap | 44.23M |
| PE | -1.08 |
| EPS | -2.1 |
| Moving Average 50 Days | 2.41 |
| Moving Average 200 Days | 2.59 |
| Change | 0.01 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $236.7 as of October 09, 2025 at a share price of $2.27. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 3 years ago, it would be worth $180.88 as of October 09, 2025 at a share price of $2.27.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis Appoints Mark Guerin as Chief Financial Officer
GlobeNewswire Inc.
Sep 25, 2025 11:30 AM GMT
MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease
Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
GlobeNewswire Inc.
Sep 16, 2025 11:30 AM GMT
MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease
Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease